Cantor Fitzgerald Initiates Coverage on Aardvark Therapeutics (NASDAQ:AARD)

Cantor Fitzgerald initiated coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 379.85% from the company’s current price.

Aardvark Therapeutics Price Performance

Shares of Aardvark Therapeutics stock opened at $10.42 on Monday. Aardvark Therapeutics has a 52 week low of $9.21 and a 52 week high of $19.58.

Insiders Place Their Bets

In other news, CFO Nelson Sun acquired 10,000 shares of the business’s stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $160,000.00. Following the transaction, the chief financial officer now owns 99,484 shares in the company, valued at $1,591,744. The trade was a 11.18 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Tien-Li Lee bought 16,542 shares of Aardvark Therapeutics stock in a transaction on Friday, February 14th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $264,672.00. Following the acquisition, the chief executive officer now directly owns 1,496,175 shares in the company, valued at approximately $23,938,800. This trade represents a 1.12 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.